搜索
Mediwound Ltd
MDWD添加自选
15.160USD
+0.340+2.29%
收盘 07/02, 13:00（美东）报价延迟15分钟
194.84M总市值
亏损市盈率 TTM
关键数据
14.910今开
15.240最高
52.68K成交量
亏损市盈率 TTM
亏损市盈率动
--股息TTM
0.41%换手率
14.820昨收
14.710最低
699.49K成交额
亏损市盈率静
3.90市净率
0.00%股息率 TTM
-29.90%ROA
22.50552周最高
0.88量比
-30.22M净利润
12.85M总股本
-2.0990每股收益TTM
0.18Beta
-52.35%ROE
14.14052周最低
3.58%振幅
21.90%毛利率
194.84M总市值
3.13回报/风险
2.54%风险率
TradingKey Mediwound Ltd股票评分
单位: USD 更新时间: 2026-07-02操作建议
Mediwound Ltd当前公司基本面数据相对健康，增长潜力较大。当前估值合理，在药品行业排名79/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价30.17。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Mediwound Ltd评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Mediwound Ltd亮点
亮点风险
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
业绩增长期
公司处于发展阶段，最新年度总收入16.96M美元
利润高增长
公司净利润处于行业前列，最新年度总收入16.96M美元
估值合理
公司最新PE估值-7.22，处于3年历史合理位
机构加仓
最新机构持股7.42M股，环比增加3.86%
分析师目标
根据
6
位分析师
买入
评级
30.167
目标均价
+100.04%
涨幅空间
Mediwound Ltd新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Mediwound Ltd简介
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
公司代码MDWD
公司Mediwound Ltd
CEOGonen (Ofer)
网址https://www.mediwound.com/
相关品种
热门品种
常见问题
Mediwound Ltd(MDWD)的当前股价是多少？
Mediwound Ltd(MDWD)的当前股价是 15.16。
Mediwound Ltd的股票代码是什么？
Mediwound Ltd的股票代码是MDWD。
Mediwound Ltd股票的52周最高点是多少？
Mediwound Ltd股票的52周最高点是22.50。
Mediwound Ltd股票的52周最低点是多少？
Mediwound Ltd股票的52周最低点是14.14。
Mediwound Ltd的市值是多少？
Mediwound Ltd的市值是194.84M。
现在Mediwound Ltd(MDWD)的股票是买入、持有还是卖出？
根据分析师评级，Mediwound Ltd(MDWD)的总体评级为买入，目标价格为30.17。
Mediwound Ltd(MDWD)股票的每股收益（EPS TTM）是多少
Mediwound Ltd(MDWD)股票的每股收益（EPS TTM）是-2.10。